KR102310234B1 - Health functional food composition for improving blood circulation, and the method for preparing the same - Google Patents
Health functional food composition for improving blood circulation, and the method for preparing the same Download PDFInfo
- Publication number
- KR102310234B1 KR102310234B1 KR1020190110720A KR20190110720A KR102310234B1 KR 102310234 B1 KR102310234 B1 KR 102310234B1 KR 1020190110720 A KR1020190110720 A KR 1020190110720A KR 20190110720 A KR20190110720 A KR 20190110720A KR 102310234 B1 KR102310234 B1 KR 102310234B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- red ginseng
- composition
- safflower seed
- blood flow
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 230000017531 blood circulation Effects 0.000 title claims abstract description 49
- 235000013376 functional food Nutrition 0.000 title claims abstract description 21
- 230000036541 health Effects 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title abstract description 23
- 239000000284 extract Substances 0.000 claims abstract description 115
- 240000007594 Oryza sativa Species 0.000 claims abstract description 69
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 69
- 235000009566 rice Nutrition 0.000 claims abstract description 69
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 65
- 229940023866 safflower seed extract Drugs 0.000 claims abstract description 33
- 229920001353 Dextrin Polymers 0.000 claims description 25
- 239000004375 Dextrin Substances 0.000 claims description 25
- 235000019425 dextrin Nutrition 0.000 claims description 25
- 230000006872 improvement Effects 0.000 claims description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 235000005254 Allium ampeloprasum Nutrition 0.000 claims description 9
- 240000006108 Allium ampeloprasum Species 0.000 claims description 9
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 9
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 9
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 9
- 240000008620 Fagopyrum esculentum Species 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 9
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 4
- 238000008214 LDL Cholesterol Methods 0.000 abstract description 4
- 239000002417 nutraceutical Substances 0.000 abstract description 2
- 235000021436 nutraceutical agent Nutrition 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 230000000694 effects Effects 0.000 description 27
- 244000020518 Carthamus tinctorius Species 0.000 description 26
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000008187 granular material Substances 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 14
- 235000008504 concentrate Nutrition 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 235000009200 high fat diet Nutrition 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000219051 Fagopyrum Species 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000004898 kneading Methods 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 235000007882 dietary composition Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 3
- 102000043296 Lipoprotein lipases Human genes 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940100486 rice starch Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000020712 soy bean extract Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-O PAF Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(O)(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-O 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 244000063464 Vitex agnus-castus Species 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- -1 that is Substances 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pediatric Medicine (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 혈류 개선용 건강기능식품 조성물, 및 이의 제조 방법에 대한 것으로, 구체적으로 홍삼 추출물, 쌀눈 추출물 및 홍화씨 추출물을 포함하여 중성지방 및 LDL-콜레스테롤 수치를 현저하게 감소시킴으로써 혈류 개선 효과가 뛰어난 건강기능식품 조성물 및 이의 제조 방법에 관한 것이다.The present invention relates to a health functional food composition for improving blood flow, and a method for manufacturing the same, and specifically, by significantly reducing triglyceride and LDL-cholesterol levels, including red ginseng extract, rice bran extract and safflower seed extract, thereby improving blood flow. It relates to a nutraceutical composition and a method for preparing the same.
Description
본 발명은 혈류 개선용 건강기능식품 조성물, 및 이의 제조 방법에 대한 것으로, 구체적으로 홍삼 추출물, 쌀눈 추출물 및 홍화씨 추출물을 포함하여 중성지방 및 LDL-콜레스테롤 수치를 현저하게 감소시킴으로써 혈류 개선 효과가 뛰어난 건강기능식품 조성물 및 이의 제조 방법에 관한 것이다.The present invention relates to a health functional food composition for improving blood flow, and a method for manufacturing the same, and specifically, by significantly reducing triglyceride and LDL-cholesterol levels, including red ginseng extract, rice bran extract and safflower seed extract, thereby improving blood flow. It relates to a nutraceutical composition and a method for preparing the same.
최근, 식생활의 서구화, 운동 부족, 과도한 스트레스 등의 생활 환경의 변화에 따라 동맥경화증, 뇌경색 등의 혈액이나 순환기계에 관련한 질환 및 고지혈증, 당뇨병 등의 혈액 순환에 악영향을 미치는 질환이 증가되고 있다. 이들 질환은 미소혈관이나 모세혈관의 혈류 저하를 일으키므로 생체에 다양한 악영향을 줄 위험성이 지적되고 있다. 또한, 혈류가 피부의 가려움, 피로, 고혈압 등과도 관계가 있는 것도 보고되고 있다.Recently, according to changes in the living environment such as westernization of diet, lack of exercise, and excessive stress, diseases that adversely affect blood circulation such as arteriosclerosis and cerebral infarction and diseases related to the blood or circulatory system, such as hyperlipidemia and diabetes, are increasing. Since these diseases cause a decrease in blood flow in microvessels or capillaries, the risk of adversely affecting the living body is pointed out. It has also been reported that blood flow is also related to skin itchiness, fatigue, high blood pressure, and the like.
일반적으로 혈액순환(the circulation of blood), 즉 혈류는 혈액이 심장을 중심으로 혈관을 따라 우리의 신체를 순환하는 것으로 산소를 신체 각 조직에 공급하고 탄산가스를 방출하고, 영양소를 보급하고 대사산물을 방출하며, 여러 내분비선에서 호르몬을 운반하여 특정기관의 기능을 조절하며 그 밖에 병원균 조절작용과 체온조절, 삼투압조절, 수분조절 등의 기능을 수행하는 과정이다.In general, the circulation of blood, that is, blood circulates through the blood vessels around the heart, supplying oxygen to each body tissue, releasing carbon dioxide, supplying nutrients, and metabolites It is a process that regulates the functions of specific organs by transporting hormones from various endocrine glands, and performs other functions such as pathogen control, body temperature control, osmotic pressure control, and moisture control.
혈액순환 장애란 우리 온몸의 구석구석에 뻗어 있는 혈관이 탄력을 잃고 내벽에 콜레스테롤 등이 침착되어 혈관 내강이 좁아져 혈액순환이 원활하게 이루어지지 못하는 것을 말한다. 혈액순환 장애는 수족냉증, 손발 저림, 뒷목 당김, 어깨 결림, 기억력 감퇴, 무기력, 집중력 약화, 현기증 및 만성 피로 증상을 유발하여 정상적인 생활을 영위하는데 어려움이 많게 된다.Blood circulation disorder refers to a condition in which blood vessels extending throughout the body lose elasticity and cholesterol, etc. are deposited on the inner wall, narrowing the lumen of blood vessels, preventing smooth blood circulation. Blood circulation disorders cause cold hands and feet, numbness of hands and feet, tight neck, stiff shoulders, memory loss, lethargy, weakened concentration, dizziness, and chronic fatigue, making it difficult to lead a normal life.
혈액순환에 장애가 생겨 발생하는 심혈관계 질환인 고혈압, 동맥경화증, 심장병, 뇌졸중 등은 오늘날 성인병의 주종을 이루고 있으며, 사망률이 높은 질병으로 70세까지는 암에 의한 사망률이 가장 높으나 70세 이후에는 심혈관계 질환이 제 1의 사망원인이다. 이는 서구화된 식생활에 따라 동물성 식품의 섭취빈도가 높아져 성인의 경우 혈중 총 콜레스테롤이나 중성지질의 수준이 높아지는 경향 때문인 것으로 보인다. 이러한 지질성분의 증가는 혈액의 점성을 증가시키거나 혈류의 흐름을 방해함으로써 뇌졸중을 포함한 심혈관성 질환의 원인이 되는 것으로 알려져 있다.High blood pressure, arteriosclerosis, heart disease, stroke, etc., which are cardiovascular diseases caused by impaired blood circulation, are the main types of adult diseases today. Disease is the number one cause of death. This seems to be due to the tendency to increase the level of total cholesterol or triglycerides in the blood in adults as the frequency of intake of animal foods increases according to the westernized diet. It is known that an increase in the lipid component increases the viscosity of blood or interferes with the flow of blood, thereby causing cardiovascular diseases including stroke.
혈류 관련 기관을 보면, 혈장은 혈액응고와 관련된 응고 인자(coagulation factor)로 구성되어 있고, 혈소판, 적혈구, 면역세포 등의 혈액세포들과 다양한 상호 작용을 주고받으며 각 세포 작용의 평형상태를 유지하고 있다. 혈소판은 혈관이 손상되면 활성화되어 손상 부위에 응집됨으로써 지혈 작용을 담당하는 세포이다. 지혈 작용은 손상된 부위로부터의 혈액의 손실을 최소화하고 혈액의 정상적인 순환을 유지하기 위한 방어기전이라 할 수 있다. 정상 혈관에서는 지혈 기전의 활성화 반응과 함께 억제 반응이나 혈괴 분해 반응들이 균형을 이룸으로써 항상성을 유지하고 있다. 그러나 과도한 지혈 작용 및 혈괴의 생성은 혈액의 흐름을 방해하며 혈행 이상을 초래하여 혈전(thrombus)과 같은 병변을 유발한다. 혈전이 생성되면 정맥에서는 혈액순환장애가 야기되어 부종이나 염증 등이 발생하고 동맥에서는 허혈이나 경색을 유발하여 심근경색증, 뇌졸중, 폐동맥 경색증 등의 질환을 초래하게 된다. 이와 더불어 혈소판 활성화시 여러 가지 혈관조절 인자들(serotonin, TXA2, PAF 등)이 유리되어 혈관을 수축시킬 수 있다. 혈관이 수축되면 혈류의 흐름을 막아 혈류 속도가 변화되어 혈소판 활성화가 증폭되며 혈관 내피손상이 진행되어 심혈관의 정상적인 기능이 저해된다. 이러한 혈행 이상이 동맥경화, 심근경색, 심허혈질환 및 뇌혈관질환과 같은 혈관계질환 발병의 원인이 되는 것으로 알려져 있다(Marcus et al., 1993; Packham et al., 1994; Harker et al., 1994).Looking at blood flow-related organs, plasma is composed of coagulation factors related to blood coagulation, and it exchanges various interactions with blood cells such as platelets, red blood cells, and immune cells, and maintains the equilibrium state of each cell action. have. Platelets are cells that are activated when blood vessels are damaged and are responsible for hemostasis by aggregating at the damaged site. Hemostasis can be said to be a defense mechanism to minimize blood loss from the damaged area and to maintain normal blood circulation. In normal blood vessels, homeostasis is maintained by balancing inhibitory reactions or clot decomposition reactions along with activation of the hemostatic mechanism. However, excessive hemostasis and the formation of clots obstruct blood flow and cause abnormal blood circulation, leading to lesions such as thrombus. When a thrombus is formed, blood circulation disorder is caused in the vein, which causes edema or inflammation, and causes ischemia or infarction in the artery, resulting in diseases such as myocardial infarction, stroke, and pulmonary infarction. In addition, various vascular control factors (serotonin, TXA2, PAF, etc.) are released upon activation of platelets to constrict blood vessels. When blood vessels constrict, blood flow is blocked and blood flow speed is changed, so platelet activation is amplified, and vascular endothelial damage progresses, impairing normal cardiovascular function. Such blood circulation abnormalities are known to cause the onset of vascular diseases such as arteriosclerosis, myocardial infarction, cardio ischemic disease and cerebrovascular disease (Marcus et al., 1993; Packham et al., 1994; Harker et al., 1994). ).
혈류개선 관련 의약품, 식품 및 식품 성분이 다수 개발 보고되어 있다. 그러나, 일부 기능성 식품들은 약물중독 및 부작용에 의한 문제점이 존재하므로, 장기 복용시에도 부작용이 없어 신체에 안전하면서 효과적으로 혈류 개선 효과를 나타낼 수 있는 물질에 대한 수요가 여전히 존재한다.A number of drugs, foods, and food ingredients related to blood flow improvement have been developed and reported. However, since some functional foods have problems due to drug addiction and side effects, there is still a demand for substances that can effectively improve blood flow while being safe for the body because there are no side effects even when taken for a long time.
본 발명자들은 홍삼 추출물, 홍화씨 추출물 및 쌀눈 추출물을 특정 비율로 배합하게 되면 이들 물질의 상승작용에 의하여 인체의 혈류 개선에 뛰어난 효과를 나타낸다는 것을 발견하여 본 발명을 완성하게 되었다.The present inventors have completed the present invention by discovering that when red ginseng extract, safflower seed extract and rice bran extract are mixed in a specific ratio, the synergistic action of these substances exhibits an excellent effect on improving blood flow in the human body.
따라서, 본 발명의 목적은 혈류를 효과적으로 개선시키면서 당뇨 증상을 완화시키고 혈압을 저하시키는 데 뛰어난 효능이 있는 건강기능식품 조성물 및 이의 제조 방법을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a health functional food composition having excellent efficacy in alleviating diabetic symptoms and lowering blood pressure while effectively improving blood flow and a method for preparing the same.
또한, 본 발명의 또 다른 목적은 유효성분의 체내 흡수력은 높이면서도 유효성분 이외의 다른 첨가제를 포함하지 않는, 상기 건강기능식품의 제조방법을 제공하는 것이다.In addition, another object of the present invention is to provide a method for producing the health functional food, which does not contain other additives other than the active ingredient while increasing the absorption capacity of the active ingredient in the body.
상기한 목적을 달성하기 위하여, 본 발명은 홍삼 추출물, 홍화씨 추출물 및 쌀눈 추출물을 1 : 0.5~4 : 0.5~2의 중량비로 혼합한 배합물을 포함하는 혈류 개선용 건강기능식품 조성물을 제공한다.In order to achieve the above object, the present invention provides a health functional food composition for improving blood flow comprising a mixture of red ginseng extract, safflower seed extract and rice bran extract in a weight ratio of 1: 0.5-4: 0.5-2.
또한, 본 발명은 Also, the present invention
(1) 홍삼, 홍화씨 및 쌀눈의 추출물의 혼합물을 1 : 0.5~4 : 0.5~2의 중량비로 혼합한 다음, 이를 감압농축시켜 농축액 혼합물을 제조하는 단계;(1) mixing a mixture of extracts of red ginseng, safflower seeds and rice bran in a weight ratio of 1: 0.5-4: 0.5-2, and then concentrating it under reduced pressure to prepare a concentrate mixture;
(2) 상기 농축액 혼합물을 건조시켜 분말을 수득하는 단계;(2) drying the concentrate mixture to obtain a powder;
(3) 상기 분말을 주정을 사용하여 반죽하는 단계;(3) kneading the powder using alcohol;
(4) 상기 반죽을 숙성시키는 단계;(4) aging the dough;
(5) 상기 숙성된 반죽을 과립으로 성형하는 단계; 및(5) forming the aged dough into granules; and
(6) 상기 성형된 과립을 건조시키는 단계(6) drying the molded granules
를 포함하는 혈류 개선용 건강기능식품 조성물의 제조 방법을 제공한다.It provides a method for producing a health functional food composition for improving blood flow comprising a.
본 발명의 건강기능식품 조성물은 장기간 복용시에도 신체에 미치는 부작용이 없어 인체에 안전하면서도 혈류 개선 효과가 매우 우수하다.The health functional food composition of the present invention has no side effects on the body even when taken for a long period of time, so it is safe for the human body and has a very good blood flow improvement effect.
또한, 본 발명의 조성물은 주정을 사용하여 반죽을 수행하므로, 살균제, 방부제 등의 다른 첨가물을 함유하지 않아도 되기 때문에 첨가물의 함유에 따른 부작용을 피할 수 있으면서, 별도의 고온살균 등의 처리가 불필요하며, 섭취 후 붕해가 빨라서 유효성분의 체내 흡수력이 우수하다.In addition, since the composition of the present invention is kneaded using alcohol, it is not necessary to contain other additives such as sterilizing agents and preservatives, so side effects caused by the inclusion of additives can be avoided, and a separate treatment such as high-temperature sterilization is unnecessary. , It disintegrates quickly after ingestion, so the absorption of the active ingredient is excellent.
본 발명은 홍삼 추출물, 홍화씨 추출물 및 쌀눈 추출물을 1 : 0.5~4 : 0.5~2의 중량비, 바람직하게는 1:2:1의 중량비로 혼합한 배합물을 포함하는 혈류 개선용 건강기능식품 조성물에 관한 것이다.The present invention relates to a health functional food composition for improving blood flow comprising a mixture of red ginseng extract, safflower seed extract and rice bran extract in a weight ratio of 1: 0.5 to 4: 0.5 to 2, preferably 1: 2: 1. will be.
또한, 본 발명의 조성물은 덱스트린을 추가로 포함할 수 있으며, 이 때 홍삼 추출물, 홍화씨 추출물 및 쌀눈 추출물과 덱스트린의 혼합비는 중량비로 1 : 0.5~4 : 0.5~2 : 0.5~4이며, 바람직하게는 1:2:1:2일 수 있다.In addition, the composition of the present invention may further include dextrin, in which case the mixing ratio of red ginseng extract, safflower seed extract and rice germ extract and dextrin is 1: 0.5-4: 0.5-2: 0.5-4 in weight ratio, preferably may be 1:2:1:2.
본 발명에서 사용되는 홍삼은 인삼(Panax ginseng C.A. Meyer)을 원재료로 사용하여, 말리지 않은 수삼을 증기 또는 기타 방법으로 쪄서 익혀 말린 것이다. 홍삼과 백삼 간에는 조사포닌 함량이나 진세노사이드의 종류에서 차이를 보이는 것으로 알려져 있다. 홍삼은 분말화하거나 물이나 주정으로 추출하여 농축 또는 발효하여 식용에 적합하도록 만들어야 하는데, 진세노사이드 Rg1과 Rb1의 합이 0.8~34㎎/g이 되도록 관리하여야 한다. 홍삼이나 그 분말 및 추출물은 오랫동안 안전하게 섭취하여 온 식품이며, 심각한 독성은 보고된 바 없다. 홍삼은 면역력 증진, 피로 개선, 혈소판 응집 억제를 통한 혈액 흐름에 도움이 되는 것으로 식약처에서 그 기능성이 인정되었다.Red ginseng used in the present invention uses ginseng ( Panax ginseng CA Meyer) as a raw material, and steams or other methods to steam and dry undried fresh ginseng. It is known that there is a difference between red ginseng and white ginseng in the content of saponin or the type of ginsenoside. Red ginseng should be powdered or extracted with water or alcohol to be concentrated or fermented to make it suitable for consumption, but the sum of ginsenosides Rg1 and Rb1 should be controlled to be 0.8~34mg/g. Red ginseng or its powder and extract are foods that have been safely ingested for a long time, and serious toxicity has not been reported. Red ginseng has been recognized for its functionality by the Ministry of Food and Drug Safety as it helps blood flow by enhancing immunity, improving fatigue, and inhibiting platelet aggregation.
본 발명에서 사용되는 홍화씨는 국화과 식물인 잇꽃(Carthamus tinctorius L.)의 씨앗으로서, 기름을 짜거나 향신료, 약용으로 사용된다. 홍화씨는 리놀레산(linolic acid)을 함유해 동맥경화, 고지혈증 등을 예방하는 데 도움이 된다. 리놀레산은 불포화지방산의 하나로 지방 축적에 관여하는 리포단백리파제(LPL, lipoproteinlipase)의 활성을 저해한다. 리포단백리파제 활성이 증가하면 중성지방의 지방 세포 흡수가 왕성해지는데, 리놀레산은 이를 억제하는 것이다. 또한, 체지방의 에너지 생성을 촉진해 축적된 지방을 분해하므로 체지방 감소에도 도움을 줄 수 있는 것으로 알려져 있다.The safflower seed used in the present invention is a safflower plant in the Asteraceae family ( Carthamus). tinctorius L.), used for oil extraction, spice, and medicine. Safflower seeds contain linoleic acid, which helps to prevent arteriosclerosis and hyperlipidemia. Linoleic acid, one of the unsaturated fatty acids, inhibits the activity of lipoproteinlipase (LPL), which is involved in fat accumulation. When lipoprotein lipase activity is increased, adipocyte absorption of triglycerides is enhanced, and linoleic acid inhibits this. In addition, it is known that it can help reduce body fat by promoting energy generation of body fat and decomposing accumulated fat.
본 발명에서 사용되는 쌀눈은 쌀을 도정할 때 부산물로 수득되는 쌀겨로부터 분리되는 것이다. 쌀눈에는 이노시톨(수용성비타민B 복합제이용)이 풍부하게 함유되어 있으며, 이에 의해 뇌세포에 영양 공급을 하며, 숙면을 취하는 데 도움이 되고, 우울증 및 공황장애의 치료 효능이 있으며, 갑작스런 공포감을 줄이고, 치매 예방 효과 및 지방간 해소 효능이 있는 것으로 보고되었다. 또한 지방과 콜레스테롤의 체내 이용을 도우며 동맥경화 예방, 뱃살 감소 효능 등도 보고되었다. 또한, 쌀눈에는 감마 오리자놀 또한 다량 함유되어 있는데, 이는 강력한 항산화제로서 항암, 항노화 등의 효능이 있으며, 운동 후 회복을 돕고 통증을 감소시키는 작용을 한다.Rice germ used in the present invention is to be separated from rice bran obtained as a by-product when milling rice. Rice buds are rich in inositol (using a water-soluble vitamin B complex), thereby supplying nutrients to brain cells, helping to get a good night's sleep, treating depression and panic disorder, reducing sudden fear, It has been reported to have an effect of preventing dementia and resolving fatty liver. It also helps the body use fat and cholesterol, and has been reported to prevent arteriosclerosis and reduce belly fat. In addition, rice germ also contains a large amount of gamma oryzanol, which is a powerful antioxidant that has anti-cancer and anti-aging effects, helps recovery after exercise and reduces pain.
본 발명에서 사용되는 쌀눈의 수득은 당업계에서 통상적으로 사용되는 공정을 이용하여 이루어질 수 있으며, 한국등록특허 제10-0586707호(2006년 6월 8일 공고)에 개시된 “쌀눈의 열처리방법”을 사용하여 이루어질 수도 있고, 구체적으로 상기 방법은 하기의 단계를 포함한다:Obtaining the rice germ used in the present invention can be made using a process commonly used in the art, and the "heat treatment method of rice germ" disclosed in Korean Patent No. 10-0586707 (June 8, 2006 announcement) can also be made using, specifically, the method comprising the steps of:
(1) 현미를 도정하여 얻은 미강을 30~40 mesh의 진동체를 통해 쌀눈과 쌀겨를 분리하는 제1단계,(1) The first step of separating rice bran from rice bran through a vibrating sieve of 30-40 mesh for rice bran obtained by milling brown rice,
(2) 상기 제1단계에서 분리된 쌀겨를 110~130℃에서 5~20분 동안 건열처리한 후 냉각시킴으로써 지방분해효소의 활성을 억제시켜 안정화된 쌀겨를 제조하는 제2단계,(2) a second step of preparing stabilized rice bran by inhibiting the activity of lipolytic enzyme by drying the rice bran separated in the first step for 5 to 20 minutes at 110 to 130° C. and cooling it;
(3) 상기 제1단계에서 분리된 나머지 쌀눈을 140~160℃에서 5~20분 동안 건열처리한 후 냉각시킴으로써 지방산화효소의 활성을 억제시켜 안정화된 쌀눈을 제조하는 제3단계, 및(3) The third step of producing stabilized rice germ by inhibiting the activity of fatty acid oxidase by drying the remaining rice germ separated in the first step for 5 to 20 minutes at 140-160° C. and then cooling it; and
(4) 상기 제2단계에서 지방분해효소의 활성을 억제시켜 안정화된 쌀겨 및 상기 제3단계에서 지방산화효소의 활성을 억제시켜 안정화된 쌀눈 중에서 선택된 적어도 하나를 수득하는 제4단계.(4) A fourth step of obtaining at least one selected from the stabilized rice bran by inhibiting the activity of the lipolytic enzyme in the second step and the stabilized rice bran by inhibiting the activity of the fatty acid oxidase in the third step.
본 발명에 따른 조성물은 홍삼 추출물, 홍화씨 추출물 및 쌀눈 추출물을 1 : 0.5~4 : 0.5~2, 보다 바람직하게는 1:2:1의 중량비로 혼합한 배합물을 포함한다.The composition according to the present invention includes a combination of red ginseng extract, safflower seed extract and rice bran extract in a weight ratio of 1: 0.5 to 4: 0.5 to 2, more preferably 1: 2: 1.
또한, 본 발명에 따른 조성물은 덱스트린을 추가로 포함할 수 있으며, 이 때 홍삼 추출물, 홍화씨 추출물, 쌀눈 추출물 및 덱스트린은 1 : 0.5~4 : 0.5~2 : 0.5~4의 중량비, 바람직하게는 1:2:1:2의 중량비로 포함될 수 있다.In addition, the composition according to the present invention may further include dextrin, wherein the red ginseng extract, safflower seed extract, rice bud extract and dextrin are in a weight ratio of 1: 0.5-4: 0.5-2: 0.5-4, preferably 1 It may be included in a weight ratio of :2:1:2.
또한, 본 발명에 따른 조성물은 상기 성분들 이외에 혈류개선에 도움이 되는 것으로 당업계에 알려져 있는 다른 성분을 더 포함할 수 있다. 구체적으로, 본 발명에 따른 조성물은 상기 성분들 이외에, 헛개나무 열매, 콩나물, 부추 및 메밀로 이루어진 군에서 선택되는 1종 이상의 추출물을 더 포함할 수 있다. 또한, 이들 분말은 조성물 중 홍삼 추출물, 홍화씨 추출물 및 쌀눈 추출물의 총 중량을 기준으로 10~100중량%의 양으로 포함될 수 있다.In addition, the composition according to the present invention may further include other components known in the art to help improve blood flow in addition to the above components. Specifically, the composition according to the present invention may further include one or more extracts selected from the group consisting of Heotgae fruit, bean sprouts, leek and buckwheat in addition to the above components. In addition, these powders may be included in an amount of 10 to 100% by weight based on the total weight of the red ginseng extract, safflower seed extract and rice germ extract in the composition.
본 발명에 따른 조성물에 있어서, 홍삼, 홍화씨 및 쌀눈의 추출물은 홍삼, 홍화씨 및 쌀눈의 혼합물로부터 수득한 것을 사용할 수도 있고, 홍삼, 홍화씨 및 쌀눈 각각의 추출물을 제조한 다음, 이들 추출물을 혼합한 것을 사용할 수도 있다.In the composition according to the present invention, the extract of red ginseng, safflower seed and rice germ may be obtained from a mixture of red ginseng, safflower seed and rice germ, and each extract of red ginseng, safflower seed and rice germ is prepared, and then these extracts are mixed. can also be used.
본 발명에 있어서, 홍삼, 홍화씨 및 쌀눈 추출물의 제조는 당업계에서 일반적으로 사용되는 공정을 사용하여 이루어질 수 있으며, 어느 특정 공정으로 제한되는 것은 아니다.In the present invention, the production of red ginseng, safflower seed and rice germ extract may be made using a process generally used in the art, and is not limited to any specific process.
예를 들어, 본 발명에서 사용되는 홍삼, 홍화씨 및 쌀눈 추출물은 추출 용매로서 물, 에탄올, 또는 물과 에탄올의 혼합물을 이용하여 수득될 수 있으며, 바람직하게는 추출 용매로서 50~90%(v/v) 주정 또는 물, 보다 바람직하게는 80%(v/v) 주정 또는 열수를 이용할 수 있다. 보다 바람직하게는, 홍삼, 홍화씨 및 쌀눈으로부터 80%(v/v) 주정과 열수를 각각 이용하여 수득한 추출물의 혼합물을 본 발명에 따른 조성물의 제조에 이용할 수 있다.For example, the red ginseng, safflower seed and rice germ extract used in the present invention can be obtained by using water, ethanol, or a mixture of water and ethanol as an extraction solvent, preferably 50 to 90% (v/ v) Alcohol or water, more preferably 80% (v/v) alcohol or hot water may be used. More preferably, a mixture of extracts obtained by using 80% (v/v) alcohol and hot water from red ginseng, safflower seeds and rice germ, respectively, may be used in the preparation of the composition according to the present invention.
본 발명에 따른 건강기능식품 조성물은 환제, 정제, 캡슐제, 과립, 시럽, 음료 등의 형태로 제형화될 수 있다. 제형화의 방법은 특별히 한정되지 않으며, 당업계에서 통상적으로 사용되는 공정에 의해 수행될 수 있다.The health functional food composition according to the present invention may be formulated in the form of pills, tablets, capsules, granules, syrups, beverages, and the like. The method of formulation is not particularly limited and may be performed by a process commonly used in the art.
예를 들어, 과립의 형태로 제형화될 경우, 홍삼, 홍화씨 및 쌀눈의 추출물 혼합물을 분말화한 다음, 이를 성형 및 건조하는 공정으로 이루어질 수 있으며, 구체적으로는 다음과 같은 단계를 포함하는 방법으로 수행될 수 있다:For example, when formulated in the form of granules, the extract mixture of red ginseng, safflower seeds and rice germ can be powdered, and then formed and dried. Specifically, a method comprising the following steps It can be done:
(1) 홍삼, 홍화씨 및 쌀눈의 추출물의 혼합물을 특정 비율로 혼합한 다음, 이를 감압농축시켜 농축액 혼합물을 제조하는 단계;(1) mixing a mixture of extracts of red ginseng, safflower seeds and rice germ in a specific ratio, and then concentrating it under reduced pressure to prepare a concentrate mixture;
(2) 상기 농축액 혼합물을 건조시켜 분말을 수득하는 단계;(2) drying the concentrate mixture to obtain a powder;
(3) 상기 분말을 에탄올, 물 또는 이들의 혼합물, 바람직하게는 60 내지 90%(v/v) 주정, 보다 바람직하게는 70%(v/v) 주정을 사용하여 반죽하는 단계;(3) kneading the powder using ethanol, water or a mixture thereof, preferably 60 to 90% (v/v) alcohol, more preferably 70% (v/v) alcohol;
(4) 상기 반죽의 살균 및 주정의 반죽 내 균질화 및 고압착을 위하여 실온에서 8~15시간 동안 숙성시키는 단계;(4) aging at room temperature for 8 to 15 hours for sterilization of the dough and for homogenization and high pressure in the dough of alcohol;
(5) 상기 숙성된 반죽을 과립기를 이용하여 과립으로 성형하는 단계; 및(5) forming the aged dough into granules using a granulator; and
(6) 상기 성형된 과립을 수분 함량이 약 4~8%, 바람직하게는 약 7%가 되도록 30%의 상대습도, 65~70℃의 온도에서 건조시키는 단계.(6) drying the molded granules at a relative humidity of 30% and a temperature of 65 to 70° C. so that the moisture content is about 4 to 8%, preferably about 7%.
상기 방법은 (6) 단계 후, (7) 상기 건도된 과립을 용량에 따른 1회 복용분씩 나누어 포장하는 단계를 더 포함할 수 있다.The method may further include, after step (6), (7) packaging the dried granules by dividing each dose according to the dose.
상기 방법의 (1) 단계에서 농축액 혼합물에 덱스트린을 추가로 혼합할 수도 있다. 이 때, 홍삼 추출물, 홍화씨 추출물, 쌀눈 추출물 및 덱스트린은 1 : 0.5~4 : 0.5~2 : 0.5~4의 중량비, 바람직하게는 1:2:1:2의 중량비로 혼합될 수 있다.In step (1) of the above method, dextrin may be further mixed with the concentrate mixture. At this time, the red ginseng extract, safflower seed extract, rice bran extract and dextrin may be mixed in a weight ratio of 1: 0.5-4: 0.5-2: 0.5-4, preferably 1:2: 1:2 by weight.
또한, 상기 방법의 (1) 단계에서는 헛개나무 열매 추출물, 콩나물 추출물, 부추 추출물 및 메밀 추출물로 이루어진 군에서 선택되는 1종 이상의 추출물을 더 포함시켜 농축액 혼합물을 제조할 수 있다.In addition, in step (1) of the method, it is possible to prepare a concentrate mixture by further including one or more extracts selected from the group consisting of Heotgae tree fruit extract, bean sprouts extract, leek extract, and buckwheat extract.
상기한 본 발명의 제조방법은, 특별히 언급하지 않는 경우에는 당업계에 공지되어 있는 통상적인 방법으로 수행될 수 있다.The above-described manufacturing method of the present invention may be performed by a conventional method known in the art, unless otherwise specified.
본 발명에 따른 건강기능식품은 홍삼에 포함된 진세노사이드 Rb1, Rg1 및 Rg3S의 함량이 식약청 효능 기준에 부합되도록 일일 복용량을 설정할 수 있으며, 바람직하게는 Rg1+Rg1+Rg3S의 일일 복용량이 10mg이 되도록 한다.The health functional food according to the present invention can set the daily dose so that the contents of ginsenosides Rb1, Rg1 and Rg3S contained in red ginseng meet the efficacy standards of the Food and Drug Administration, preferably, the daily dose of Rg1 + Rg1 + Rg3S is 10 mg. make it possible
본 발명에 따른 건강기능식품은 주정을 사용하여 반죽 및 숙성하기 때문에 살균, 살충, 보존기간 연장, 제형 형성과 제조의 편리성을 위하여 당업계에서 통상적으로 사용되는 어떠한 첨가물도 포함할 필요가 없어서 효율적이다. 또한, 주정을 사용하기 때문에 조성물의 건조 시간을 단축시키는 효과가 얻어지며, 복용시에 용이하게 붕해되어 복용이 편리하고 체내 흡수가 빠르며, 유효성분의 체내 흡수력이 우수하다.Since the health functional food according to the present invention is kneaded and aged using alcohol, it is efficient because it does not need to contain any additives commonly used in the art for sterilization, insecticide, extension of shelf life, and convenience of formulation and manufacturing. am. In addition, since alcohol is used, the effect of shortening the drying time of the composition is obtained, and it disintegrates easily when taken, so that it is convenient to take and is quickly absorbed into the body, and the absorption of the active ingredient is excellent.
본 발명에 따라 제조된 건강기능식품은 유효성분과 지표성분의 함량 분해 또는 역가 감소가 방지될 수 있으며, 다른 첨가제를 포함하지 않고도 체내 흡수율이 높다.The health functional food manufactured according to the present invention can be prevented from decomposing the content of the active ingredient and the indicator component or reducing the potency, and has a high absorption rate in the body without including other additives.
이하 본 발명의 내용을 실시예를 통하여 구체적으로 설명하도록 한다. 그러나 다음의 실시예는 본 발명을 보다 상세하게 설명하기 위한 것으로, 본 발명의 권리범위를 이에 한정하고자 하는 것은 아니다.Hereinafter, the contents of the present invention will be described in detail through examples. However, the following examples are intended to illustrate the present invention in more detail, and are not intended to limit the scope of the present invention.
[실시예 1] 홍삼 추출물, 홍화씨 추출물, 쌀눈 추출물 및 덱스트린의 배합물을 포함하는 조성물의 제조[Example 1] Preparation of a composition comprising a combination of red ginseng extract, safflower seed extract, rice bran extract and dextrin
6년근 홍삼, 홍화씨 및 쌀눈 각각의 원료에 용매를 원료 중량 대비 10배의 양으로 가하였으며, 이 때 80%(v/v) 주정을 가하여 80℃에서 10시간 동안 추출하고, 1차 추출 후 원료 중량 대비 10배의 80%(v/v) 주정을 가하여 80℃에서 10시간 동안 2회 반복 추출하였다(1차 추출). 그 다음, 원료 중량 대비 10배 량의 물을 가하고, 90℃에서 3회 반복 추출하였다(2차 추출).To each raw material of 6-year-old red ginseng, safflower seed and rice germ, a solvent was added in an amount 10 times the weight of the raw material. At this time, 80% (v/v) alcohol was added and extracted at 80 ° C. 80% (v/v) alcohol 10 times the weight was added and extracted twice at 80° C. for 10 hours (primary extraction). Then, 10 times the amount of water compared to the weight of the raw material was added, and extraction was repeated three times at 90° C. (second extraction).
이렇게 얻은 80%(v/v) 주정 추출물을 여과하고, 90℃ 물의 열수 추출물을 20℃까지 냉각시킨 후, 추출물을 7,000rpm으로 원심분리한 다음, 80%(v/v) 주정 추출물(1차 추출)과 열수 추출물(2차 추출)을 혼합하여 65℃에서 감압농축시켜 수분함량이 35%인 농축액을 얻었다. 홍삼, 홍화씨 및 쌀눈의 주정 추출물과 열수 추출물을 합한 수율은 10~11%이었다.The 80% (v/v) alcohol extract thus obtained was filtered, and the hot water extract of 90° C. water was cooled to 20° C., the extract was centrifuged at 7,000 rpm, and then the 80% (v/v) alcohol extract (primary extraction) and hot water extract (secondary extraction) were mixed and concentrated under reduced pressure at 65° C. to obtain a concentrate having a water content of 35%. The combined yield of red ginseng, safflower seed and rice germ extract and hot water extract was 10 to 11%.
상기에서 수득한 홍삼, 홍화씨 및 쌀눈 각각의 추출물과 덱스트린을 아래 표 1의 비율로 배합하여 혼합하였다.Each of the extracts of red ginseng, safflower seed and rice germ obtained above and dextrin were mixed in the ratio shown in Table 1 below.
상기와 같은 비율로 혼합한 혼합물을 70℃에서 건조시켜 분말을 수득한 다음, 제조공정 중 유효성분의 안정화 및 균 사멸을 위하여 물 대비 주정의 함량이 70%(v/v)인 주정을 상기 분말에 소량씩 첨가하면서 반죽하였다. 제조된 반죽의 균질화와 살균 및 70%(v/v) 주정의 균등한 분포를 위하여, 제조된 반죽에 약 3kg/cm2의 압력을 가하면서 70mmHg 이하 진공을 30분간 건 후 10시간 실온에서 숙성시키고 난 후, 이를 과립의 입자 크기가 일정하도록 과립기를 사용하여 과립을 형성한 다음, 수분 함량이 약 7%가 되도록 건조시키고, 포장하여 혈류개선용 조성물을 제조하였다.The mixture mixed in the same ratio as above was dried at 70° C. to obtain a powder, and then, in order to stabilize the active ingredient and kill the mycelium during the manufacturing process, alcohol having an alcohol content of 70% (v/v) relative to water was added to the powder. It was kneaded while adding little by little to it. For homogenization and sterilization of the prepared dough, and for even distribution of 70% (v/v) alcohol , apply a pressure of about 3 kg/cm 2 to the prepared dough and apply a vacuum of 70 mmHg or less for 30 minutes, then ripen at room temperature for 10 hours After this, granules were formed using a granulator so that the particle size of the granules was constant, and then dried to a moisture content of about 7%, and packaged to prepare a composition for improving blood flow.
[실시예 2] 홍삼 추출물, 홍화씨 추출물, 쌀눈 추출물, 헛개나무 열매 추출물 및 덱스트린의 배합물을 포함하는 조성물의 제조[Example 2] Preparation of a composition comprising a combination of red ginseng extract, safflower seed extract, rice bud extract, Heotgae tree fruit extract and dextrin
상기 실시예 1과 동일한 방법으로 조성물을 제조하되, 단 홍삼 추출물 : 홍화씨 추출물 : 쌀눈 추출물 : 헛개나무 열매 추출물 : 덱스트린은 1 : 2 : 1 : 2 : 2(중량 기준)의 비율로 배합하였다.A composition was prepared in the same manner as in Example 1, except that red ginseng extract: safflower seed extract: rice bud extract: hutgae tree fruit extract: dextrin was mixed in a ratio of 1: 2: 1: 2: 2 (by weight).
[실시예 3] 홍삼 추출물, 홍화씨 추출물, 쌀눈 추출물, 콩나물 추출물 및 덱스트린의 배합물을 포함하는 조성물의 제조[Example 3] Preparation of a composition comprising a combination of red ginseng extract, safflower seed extract, rice bud extract, bean sprout extract and dextrin
상기 실시예 1과 동일한 방법으로 조성물을 제조하되, 단 홍삼 추출물 : 홍화씨 추출물 : 쌀눈 추출물 : 콩나물 추출물 : 덱스트린은 1 : 2 : 1 : 2 : 2(중량 기준)의 비율로 배합하였다.A composition was prepared in the same manner as in Example 1, except that red ginseng extract: safflower seed extract: rice bud extract: bean sprout extract: dextrin was formulated in a ratio of 1: 2: 1: 2: 2: 2 (by weight).
[실시예 4] 홍삼 추출물, 홍화씨 추출물, 쌀눈 추출물, 부추 추출물 및 덱스트린의 배합물을 포함하는 조성물의 제조[Example 4] Preparation of a composition comprising a combination of red ginseng extract, safflower seed extract, rice bud extract, leek extract and dextrin
상기 실시예 1과 동일한 방법으로 조성물을 제조하되, 단 홍삼 추출물 : 홍화씨 추출물 : 쌀눈 추출물 : 부추 추출물 : 덱스트린은 1 : 2 : 1 : 2 : 2(중량 기준)의 비율로 배합하였다.A composition was prepared in the same manner as in Example 1, except that the red ginseng extract: safflower seed extract: rice bud extract: leek extract: dextrin was formulated in a ratio of 1: 2: 1: 2: 2: 2 (by weight).
[실시예 5] 홍삼 추출물, 홍화씨 추출물, 쌀눈 추출물, 메밀 추출물 및 덱스트린의 배합물을 포함하는 조성물의 제조[Example 5] Preparation of a composition comprising a combination of red ginseng extract, safflower seed extract, rice bran extract, buckwheat extract and dextrin
상기 실시예 1과 동일한 방법으로 조성물을 제조하되, 단 홍삼 추출물 : 홍화씨 추출물 : 쌀눈 추출물 : 메밀 추출물 : 덱스트린은 1 : 2 : 1 : 2 : 2(중량 기준)의 비율로 배합하였다.A composition was prepared in the same manner as in Example 1, except that red ginseng extract: safflower seed extract: rice bran extract: buckwheat extract: dextrin was formulated in a ratio of 1: 2: 1: 2: 2: 2 (by weight).
[실시예 6] 홍삼 추출물, 홍화씨 추출물, 쌀눈 추출물, 헛개나무 열매 추출물, 콩나물 추출물, 부추 추출물, 메밀 추출물 및 덱스트린의 배합물을 포함하는 조성물의 제조[Example 6] Preparation of a composition comprising a combination of red ginseng extract, safflower seed extract, rice bud extract, Heotgae tree fruit extract, bean sprout extract, leek extract, buckwheat extract and dextrin
상기 실시예 1과 동일한 방법으로 조성물을 제조하되, 단 홍삼 추출물 : 홍화씨 추출물 : 쌀눈 추출물 : 헛개나무 열매 추출물 : 콩나물 추출물 : 부추 추출물 : 메밀 추출물 : 덱스트린은 1 : 2 : 1 : 0.5 : 0.5 : 0.5 : 0.5 : 2(중량 기준)의 비율로 배합하였다.A composition was prepared in the same manner as in Example 1, except that the red ginseng extract: safflower seed extract: rice bud extract: Heotgae tree fruit extract: bean sprouts extract: leek extract: buckwheat extract: dextrin was 1: 2: 1: 0.5: 0.5: 0.5 : 0.5 : 2 (based on weight) was blended.
[비교예 1] 홍삼 추출물의 제조[Comparative Example 1] Preparation of red ginseng extract
상기 실시예 1과 동일한 과정으로 홍삼 추출물을 제조하였다.A red ginseng extract was prepared in the same manner as in Example 1.
[비교예 2] 홍화씨 추출물의 제조[Comparative Example 2] Preparation of safflower seed extract
상기 실시예 1과 동일한 과정으로 홍화씨 추출물을 제조하였다.A safflower seed extract was prepared in the same manner as in Example 1.
[비교예 3] 쌀눈 추출물의 제조[Comparative Example 3] Preparation of rice germ extract
상기 실시예 1과 동일한 과정으로 쌀눈 추출물을 제조하였다.A rice germ extract was prepared in the same manner as in Example 1.
[시험예 1] 유효성분의 감소여부 확인 시험[Test Example 1] Test to confirm the decrease of the active ingredient
상기 실시예 1에서 제조된 과립에 있어서, 제조과정 중 유효성분의 감소여부를 확인하기 위하여, 홍삼에 함유된 유효성분인 진세노사이드 Rb1, Rg1, Rg3S의 합의 함량을 식약처 공인분석 방법으로 분석을 실시하고, 그 결과를 하기 표 2에 나타내었다.In the granules prepared in Example 1, the content of the sum of ginsenosides Rb1, Rg1, and Rg3S, which are active ingredients contained in red ginseng, was analyzed by the Ministry of Food and Drug Safety certified analysis method in order to check whether the active ingredient was decreased during the manufacturing process. was carried out, and the results are shown in Table 2 below.
상기 표 2로부터, 본 발명에 따라서 제조된 조성물은 제조과정 중 유효성분의 감소문제가 일어나지 않는다는 것을 확인할 수 있다.From Table 2, it can be seen that the composition prepared according to the present invention does not cause a problem of reduction of the active ingredient during the manufacturing process.
[시험예 2] 세균의 사멸 확인 시험[Test Example 2] Bacterial death confirmation test
본 발명에서 주정을 첨가한 반죽 공정에 의하여 세균이 사멸됨을 확인하기 위하여, 반죽전 배합공정에서 사용되는 원료를 대장균으로 오염시켰다. 배합 후 실시예 1의 주정 반죽을 사별한 시료에 대하여 대장균의 사멸 유무를 확인하고, 그 결과를 하기 표 3에 나타내었다.In order to confirm that the bacteria are killed by the kneading process in which alcohol is added in the present invention, the raw materials used in the mixing process before kneading were contaminated with E. coli. After compounding, it was confirmed whether or not E. coli was killed in the sample obtained by bereavement of the alcohol dough of Example 1, and the results are shown in Table 3 below.
상기 표 3으로부터, 별도의 살균제를 사용하지 않더라도 본 발명의 주정을 사용하는 반죽 공정에 의해 대장균이 모두 사멸됨을 알 수 있다.From Table 3, it can be seen that all of E. coli is killed by the kneading process using the alcohol of the present invention even if a separate disinfectant is not used.
[시험예 3] 콜레스테롤 수치 평가[Test Example 3] Cholesterol level evaluation
6주령 래트(수컷백서)를 1주일 간 사육 후, 7주령부터 6주간 일반식이군에는 표 4의 조성의 식이 조성물을 투여하고(Group 1), 고지방식이군(High Fat Diet, HFD 45%)에는 표 4의 조성의 식이 조성물을 투여하였으며(Group 2), 다른 고지방식이군(HFD 45%)에는 표 4의 조성의 식이 조성물과 함께 실시예 1 또는 비교예 1 내지 3 중 어느 하나의 조성물을 26 mg/kg의 양으로 투여하고(Group 3 내지 6), 각 그룹의 혈행 개선 효능을 평가하였다. 구체적으로 혈행 개선 효능 평가는 혈중 총 콜레스테롤(TC), 중성지질(TG), HDL-콜레스테롤 및 LDL-콜레스테롤 수치를 측정하는 생체내(in vivo) 실험을 통해 이루어졌다.After breeding 6-week-old rats (male white paper) for 1 week, the dietary composition of Table 4 was administered to the general diet group from 7 weeks of age to 6 weeks (Group 1), and the high-fat diet group (High Fat Diet, HFD 45%) The dietary composition of the composition of Table 4 was administered (Group 2), and the other high-fat diet group (HFD 45%) was administered with the composition of any one of Examples 1 or Comparative Examples 1 to 3 together with the dietary composition of Table 4 It was administered in an amount of 26 mg/kg (Groups 3 to 6), and the blood circulation improvement efficacy of each group was evaluated. Specifically, the blood circulation improvement efficacy was evaluated through an in vivo experiment measuring blood total cholesterol (TC), triglyceride (TG), HDL-cholesterol and LDL-cholesterol levels.
경구투여에 따른 혈중 총 콜레스테롤(TC), 중성지질(TG), HDL-콜레스테롤 및 LDL-콜레스테롤 수치 측정 결과는 하기 표 7에 나타내었다(단위: mg/dl).The measurement results of total cholesterol (TC), triglyceride (TG), HDL-cholesterol and LDL-cholesterol levels in blood according to oral administration are shown in Table 7 below (unit: mg/dl).
Group 2
Group 3
상기 표 7을 보면, 홍삼, 홍화씨 또는 쌀눈의 단독 투여군인 Group 9 내지 11에서는 총 콜레스테롤, 중성지질, HDL 및 LDL 수치 전부에 있어서 개선 효과를 거의 보이지 않은 반면, 홍삼 추출물, 홍화씨 추출물, 쌀눈 추출물 및 덱스트린의 복합 제제인 실시예 1을 투여한 Group 3의 경우에는 전 항목에 있어서 우수한 개선 효과를 나타낸다는 것을 확인할 수 있으며, 그 개선 정도에 있어 현저한 차이를 보여 3가지 물질의 병용에 따른 시너지 효과가 있음을 알 수 있다.Referring to Table 7, groups 9 to 11, which are groups administered alone with red ginseng, safflower seed or rice germ, showed little improvement on all cholesterol, triglyceride, HDL and LDL levels, whereas red ginseng extract, safflower seed extract, rice germ extract and In the case of Group 3 administered with Example 1, which is a combination formulation of dextrin, it can be confirmed that excellent improvement effects are exhibited in all items, and the synergistic effect according to the combination of the three substances is shown with a significant difference in the degree of improvement. it can be seen that there is
이에 더하여, 홍삼, 홍화씨 및 쌀눈의 복합 제제 이외에 다른 성분을 추가로 포함하는 실시예 2 내지 6을 투여한 Group 4 내지 8의 경우에는 총 콜레스테롤, 중성지질, HDL 및 LDL 수치 개선 정도에 있어서 보다 우수한 효과를 나타낸다는 것을 확인할 수 있다.In addition, in the case of Groups 4 to 8 administered with Examples 2 to 6, which additionally contained other ingredients in addition to the complex formulation of red ginseng, safflower seeds and rice bran, the total cholesterol, triglyceride, HDL and LDL levels were improved. It can be seen that the effect is shown.
[시험예 4] 인체에서의 혈액 순환 개선 효과 평가[Test Example 4] Evaluation of the effect of improving blood circulation in the human body
인체 적용 효능 시험을 위하여 40세 이상의 혈액순환장애를 갖고 있는 남, 녀 총 40명을 무작위로 10명씩 4개 군으로 나눈 다음, 이들을 대상으로 실시예 1 제품, 및 비교예 1 내지 3의 제품 중 어느 하나를 각각 1일 복용량 분량으로 1일 2회씩 6주일간 섭취하게 하고, 혈액 순환 개선으로 인한 효과를 평가하도록 하였으며, 그 결과를 하기 표 8에 나타내었다.For the human application efficacy test, a total of 40 males and females with blood circulation disorders over 40 years of age were randomly divided into 4 groups of 10 people, and then, among the products of Example 1 and Comparative Examples 1 to 3, Either one was ingested twice a day for 6 weeks in a daily dosage amount, respectively, and the effect due to blood circulation improvement was evaluated, and the results are shown in Table 8 below.
상기 표 8을 보면, 홍삼 추출물, 홍화씨 추출물 또는 쌀눈 추출물을 단독 투여한 경우에는 거의 효과를 보이지 않은 반면, 실시예 1을 투여한 경우에는 대부분의 참가자들이 분명한 혈액 개선 효과를 나타낸 것을 알 수 있다.Referring to Table 8, it can be seen that, when the red ginseng extract, the safflower seed extract, or the rice bran extract was administered alone, little effect was observed, whereas when Example 1 was administered, most participants showed a clear blood improvement effect.
[시험예 5] 유효성분 함량에 따른 혈액 순환 개선 효과 평가[Test Example 5] Evaluation of blood circulation improvement effect according to active ingredient content
하기 표 9와 같은 일일 복용량의 유효성분 함량 구성에 따라 상기 실시예 1에 기재된 방법으로 혈류 개선용 조성물 제품을 제조하여 40세 이상의 혈액순환장애를 갖고 있는 남, 녀 총 120명을 무작위로 10명씩 12개 군으로 나눈 다음, 이들을 대상으로 1일 복용량 분량으로 1일 2회씩 6주일간 섭취하게 하고, 혈액 순환 개선으로 인한 효과를 평가하도록 하였으며, 그 결과를 하기 표 10에 나타내었다.According to the composition of the active ingredient content of the daily dose as shown in Table 9 below, a composition product for improving blood flow was prepared by the method described in Example 1, and a total of 120 men and women with blood circulation disorders over 40 years of age were randomly assigned to 10 people each. After dividing into 12 groups, the subjects were ingested twice a day for 6 weeks in a daily dosage amount, and the effect of improving blood circulation was evaluated, and the results are shown in Table 10 below.
상기 표 10을 통해, 본 발명에 따른 혈류 개선용 조성물은 성분의 함량 조합 범위 내에서 모두 우수한 혈류 개선 효과를 보이지만, 성분의 함량 조합 범위가 적절 범위를 벗어나게 되면 효능이 떨어지게 된다는 것을 알 수 있다.From Table 10, it can be seen that the composition for improving blood flow according to the present invention exhibits excellent blood flow improvement effect within the content combination range of the components, but when the content combination range of the components is out of the appropriate range, the efficacy is lowered.
[제형예 1] 환제[Formulation Example 1] Pills
실시예 1의 조성물 90mg, 찹쌀전분 5mg 및 정제수 5mg을 혼합한 후, 통상의 방법에 따라 100mg의 환제를 만들었다.After mixing 90 mg of the composition of Example 1, 5 mg of glutinous rice starch and 5 mg of purified water, 100 mg of pills were prepared according to a conventional method.
[제형예 2] 정제[Formulation Example 2] Tablet
실시예 1의 조성물 3g, 옥수수전분 0.1g, 유 당 0.11g, 스테아린산 마그네슘 2㎎을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing 3 g of the composition of Example 1, 0.1 g of corn starch, 0.11 g of lactose, and 2 mg of magnesium stearate, tableting was performed according to a conventional tablet manufacturing method to prepare tablets.
[제형예 3] 캡슐제[Formulation Example 3] Capsules
실시예 1의 조성물 2.5g, 옥수수전분 0.1g, 유 당 0.1g, 스테아린산 마그네슘 2㎎을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing 2.5 g of the composition of Example 1, 0.1 g of corn starch, 0.1 g of lactose, and 2 mg of magnesium stearate, it was filled into a gelatin capsule according to a conventional capsule preparation method to prepare a capsule.
[제형예 4] 과립[Formulation Example 4] Granules
실시예 1의 조성물 4g, 대두 추출물 50㎎, 포도당 200㎎, 옥수수전분 600㎎을 혼합한 후, 30% 에탄올 100㎎을 첨가하여 섭씨 65℃에서 건조하여 과립을 형성한 후 포에 충진하였다.After mixing 4 g of the composition of Example 1, 50 mg of soybean extract, 200 mg of glucose, and 600 mg of corn starch, 100 mg of 30% ethanol was added and dried at 65° C. to form granules, and then filled in a bag.
[제형예 5] 드링크제[Formulation Example 5] Drink
실시예 1의 조성물 1g, 구연산 0.1g, 프락토올리고당 100g, 정제수 900g을 섞어 통상의 음료 제조방법에 따라 교반, 가열, 여과, 살균, 냉장하여 드링크제를 제조하였다.1 g of the composition of Example 1, 0.1 g of citric acid, 100 g of fructooligosaccharide, and 900 g of purified water were mixed and stirred, heated, filtered, sterilized, and refrigerated according to a conventional beverage preparation method to prepare a drink.
[제형예 6] 환제[Formulation Example 6] Pills
실시예 6의 조성물 90mg, 찹쌀전분 5mg 및 정제수 5mg을 혼합한 후, 통상의 방법에 따라 100mg의 환제를 만들었다.After mixing 90 mg of the composition of Example 6, 5 mg of glutinous rice starch, and 5 mg of purified water, 100 mg of pills were prepared according to a conventional method.
[제형예 2] 정제[Formulation Example 2] Tablet
실시예 6의 조성물 3g, 옥수수전분 0.1g, 유 당 0.11g, 스테아린산 마그네슘 2㎎을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.3 g of the composition of Example 6, 0.1 g of corn starch, 0.11 g of lactose, and 2 mg of magnesium stearate were mixed, and then tableted according to a conventional tablet manufacturing method to prepare tablets.
[제형예 3] 캡슐제[Formulation Example 3] Capsules
실시예 6의 조성물 2.5g, 옥수수전분 0.1g, 유 당 0.1g, 스테아린산 마그네슘 2㎎을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing 2.5 g of the composition of Example 6, 0.1 g of corn starch, 0.1 g of lactose, and 2 mg of magnesium stearate, it was filled into a gelatin capsule according to a conventional capsule preparation method to prepare a capsule.
[제형예 4] 과립[Formulation Example 4] Granules
실시예 6의 조성물 4g, 대두 추출물 50㎎, 포도당 200㎎, 옥수수전분 600㎎을 혼합한 후, 30% 에탄올 100㎎을 첨가하여 섭씨 65℃에서 건조하여 과립을 형성한 후 포에 충진하였다.After mixing 4 g of the composition of Example 6, 50 mg of soybean extract, 200 mg of glucose, and 600 mg of corn starch, 100 mg of 30% ethanol was added and dried at 65° C. to form granules, which were then filled in a bag.
[제형예 5] 드링크제[Formulation Example 5] Drink
실시예 6의 조성물 1g, 구연산 0.1g, 프락토올리고당 100g, 정제수 900g을 섞어 통상의 음료 제조방법에 따라 교반, 가열, 여과, 살균, 냉장하여 드링크제를 제조하였다.1 g of the composition of Example 6, 0.1 g of citric acid, 100 g of fructooligosaccharide, and 900 g of purified water were mixed and stirred, heated, filtered, sterilized, and refrigerated according to a conventional beverage preparation method to prepare a drink.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190110720A KR102310234B1 (en) | 2019-09-06 | 2019-09-06 | Health functional food composition for improving blood circulation, and the method for preparing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190110720A KR102310234B1 (en) | 2019-09-06 | 2019-09-06 | Health functional food composition for improving blood circulation, and the method for preparing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210029462A KR20210029462A (en) | 2021-03-16 |
KR102310234B1 true KR102310234B1 (en) | 2021-10-08 |
Family
ID=75224035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190110720A KR102310234B1 (en) | 2019-09-06 | 2019-09-06 | Health functional food composition for improving blood circulation, and the method for preparing the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102310234B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230108734A (en) | 2022-01-09 | 2023-07-19 | 주식회사 에브릿 | Fermented composition for health food containing red ginseng to promote blood flow effect of red ginseng and oral disintegrating film material containing the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101217395B1 (en) * | 2012-07-27 | 2012-12-31 | 정미우 | Method for manufacturing red ginseng included linoleic acid |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100672902B1 (en) * | 2004-12-09 | 2007-01-24 | 함양군 | Hovenia dulcis extract for treatment of hypercholesterolemia |
KR100728055B1 (en) * | 2005-02-24 | 2007-06-13 | (주)바이오뉴트리젠 | food for preventing fatness and hyperlipemia |
KR101145426B1 (en) | 2010-03-04 | 2012-05-15 | 한국식품연구원 | Composition for improving blood flow, the preparation method thereof and health functional foods comprising thereof |
KR101424335B1 (en) | 2012-08-07 | 2014-07-28 | 예건주식회사 | Healthy and functional food for the improvement of blood flow |
KR20150117392A (en) * | 2014-04-10 | 2015-10-20 | 김광순 | Red ginseng. brush. Mountain. Rice bran. Non-powder production method |
-
2019
- 2019-09-06 KR KR1020190110720A patent/KR102310234B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101217395B1 (en) * | 2012-07-27 | 2012-12-31 | 정미우 | Method for manufacturing red ginseng included linoleic acid |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230108734A (en) | 2022-01-09 | 2023-07-19 | 주식회사 에브릿 | Fermented composition for health food containing red ginseng to promote blood flow effect of red ginseng and oral disintegrating film material containing the same |
Also Published As
Publication number | Publication date |
---|---|
KR20210029462A (en) | 2021-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102262306B1 (en) | Composition for relieving premenstrual syndrome and menstrual pain | |
CN109090597A (en) | A kind of auxiliary lower hyperlipidemia, hypertension, hyperglycemia composition and its preparation method and application | |
CN101766274B (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
KR20120003693A (en) | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine | |
KR102310234B1 (en) | Health functional food composition for improving blood circulation, and the method for preparing the same | |
KR102243873B1 (en) | Fermented pills for reducing and preventing premature dementia and manufacturing methods thereof | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
KR101744061B1 (en) | Composition for improving diabetes and bloodstream and method for preparing the same | |
KR101688002B1 (en) | Composition for preventing or treating liver diseases comprising sonicated ginseng berry | |
KR102310233B1 (en) | Health functional food composition for improving blood circulation, and the method for preparing the same | |
EP1767203A1 (en) | Fat combustion accelerator | |
KR20110051543A (en) | Composition for preventing or treating obesity comprising blueberry fermentation extract | |
JP2010512382A (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABE CONTAINING SICONIN COMPOUND AND USE | |
KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
KR20140080289A (en) | Composition for preventing or treating of oxidative brain injury and brain function disorder | |
KR101735294B1 (en) | Composition for preventing or treating of oxidative brain injury and brain function disorder | |
KR101438278B1 (en) | Composition for Prevention or Treatment of Circulatory Disorder Comprising AFG | |
KR102527154B1 (en) | Pharmaceutical composition for preventing or treating constipation with enhanced packaging stability comprising fermentation of Prunus domestica and Ficus carica as an active ingredient | |
KR101451809B1 (en) | Composition for Preventing, Treating or Improving of Metabolic Disease comprising Coix Iachryma-jobi and Cudrania tricuspidata Leaf as an Active Ingredient | |
KR101487245B1 (en) | Yakgwa comprising red ginseng and Preparation method thereof | |
KR20190084732A (en) | A composition for improving, preventing and treating obesity comprising fermented pollack skin | |
KR100539457B1 (en) | Composition For Preventing And Treating Hyperlipidemia, Arteriosclerosis And Fatty Liver Comprising The Extract Of Sophorae Fructus | |
KR20080094132A (en) | Compositions for suppressing obesity | |
TWI701035B (en) | Uses of fu-ling (poria cocos) extract and tumulosic acid in protecting muscles | |
KR20220056612A (en) | Compositions for the prevention or treatment of obesity or diabetes mellitus and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |